APA-referens (7:e uppl.)

Chapman, K., Pavord, I., Paggiaro, P., Sciurba, F., Bafadhel, M., Bradford, E., . . . Yancey, S. (2018). Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function. American Thoracic Society.

Chicago-referens (17:e uppl.)

Chapman, K., et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function. American Thoracic Society, 2018.

MLA-referens (9:e uppl.)

Chapman, K., et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function. American Thoracic Society, 2018.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.